The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

…, TP Cujec, CM Wiethoff, JL Blackbourne… - Science translational …, 2021 - science.org
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat
for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies …

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

…, J Davies, TP Cujec, CM Wiethoff, JL Blackbourne… - BioRxiv, 2020 - biorxiv.org
SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed.
Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led …

Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents

…, JA Wijsman, HW Smith, JL Blackbourne… - …, 2015 - academic.oup.com
The tumorigenic potential of dulaglutide was evaluated in rats and transgenic mice. Rats
were injected sc twice weekly for 93 weeks with dulaglutide 0, 0.05, 0.5, 1.5, or 5 mg/kg …

Effects of dulaglutide on thyroid C cells and serum calcitonin in male monkeys

JL Vahle, RA Byrd, JL Blackbourne, JA Martin… - …, 2015 - academic.oup.com
Glucagon-like peptide-1 (GLP-1) receptor agonists, used for the treatment of type 2 diabetes,
have caused hyperplasia/neoplasia of thyroid C cells in rodent carcinogenicity studies. …

An investigative study of pancreatic exocrine biomarkers, histology, and histomorphometry in male Zucker diabetic fatty (ZDF) rats given dulaglutide by subcutaneous …

…, RA Byrd, J Meehan, JL Blackbourne… - Toxicologic …, 2015 - journals.sagepub.com
Glucagon-like peptide-1 (GLP-1) receptor agonist therapy has been implicated as a possible
risk factor for acute pancreatitis in patients with type 2 diabetes. Dulaglutide is a long-acting …

Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union

RA Byrd, RA Owens, JL Blackbourne… - Regulatory Toxicology …, 2017 - Elsevier
Basaglar ® /Abasaglar ® (Lilly insulin glargine [LY IGlar]) is a long-acting human insulin
analogue drug product granted marketing authorisation as a biosimilar to Lantus ® (Sanofi …

Effects of the GLP-1 receptor agonist dulaglutide on the structure of the exocrine pancreas of cynomolgus monkeys

JL Vahle, RA Byrd, JL Blackbourne… - Toxicologic …, 2015 - journals.sagepub.com
Clinical and nonclinical studies have implicated glucagon-like peptide-1 (GLP-1) receptor
agonist therapy as a risk factor for acute pancreatitis in patients with type 2 diabetes. Therefore…

Chronic toxicology studies of basal insulin peglispro in rats and dogs: A novel, PEGylated insulin lispro analog with a prolonged duration of action

RA Byrd, JL Blackbourne, MP Knadler… - Toxicologic …, 2017 - journals.sagepub.com
Basal insulin peglispro (BIL) consists of insulin lispro with a 20-kDa polyethylene glycol (PEG)
moiety covalently attached to lysine B28. Because chronic parenteral administration of …

Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca …

WJ Komocsar, JL Blackbourne… - Journal of …, 2016 - Taylor & Francis
The potential immunotoxicity of tabalumab was assessed as a component of standard pre-clinical
toxicology studies in cynomolgus monkeys. To evaluate potential tabalumab-…

Flow cytometric determination of P-glycoprotein expression on blast cells from pediatric leukemia patients

JL Blackbourne - 1997 - scholarworks.iupui.edu
This document only includes an excerpt of the corresponding thesis or dissertation. To request a
digital scan of the full text, Page 1 This document only includes an excerpt of the corresponding …